Sign In
Buy BAYRY
$13.89
-0.110 (-0.786%)
At Close: Jul 31, 2026
Why Bayer Aktiengesellschaft (BAYRY) is a Top Value Stock for the Long-Term
10:40am, Wednesday, 11'th Feb 2026
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Are You Looking for a Top Momentum Pick? Why Bayer Aktiengesellschaft (BAYRY) is a Great Choice
01:01pm, Tuesday, 10'th Feb 2026
Does Bayer Aktiengesellschaft (BAYRY) have what it takes to be a top stock pick for momentum investors? Let's find out.
Here's Why Bayer Aktiengesellschaft (BAYRY) is a Strong Momentum Stock
10:52am, Monday, 09'th Feb 2026
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Oakmark International Strategy Q4 2025 Contributors And Detractors
09:13am, Sunday, 08'th Feb 2026
Oakmark International Strategy Q4 2025 Contributors And Detractors
Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Share Price Passes Above Two Hundred Day Moving Average – Should You Sell?
04:38am, Saturday, 07'th Feb 2026
Bayer Aktiengesellschaft (OTCMKTS:BAYRY - Get Free Report)'s stock price crossed above its 200-day moving average during trading on Friday. The stock has a 200-day moving average of $9.25 and traded a
Bayer Aktiengesellschaft (BAYRY) Discusses OCEANIC-STROKE Phase III Results and Asundexian in Secondary Stroke Prevention Transcript
Bayer's Asundexian Shows 26% Stroke Reduction in Late-Stage Study
11:50am, Friday, 06'th Feb 2026
Bayer presents positive data on asundexian, which shows superior efficacy with no added bleeding risk, boosting hopes for regulatory approval.
Are Medical Stocks Lagging Bayer (BAYRY) This Year?
10:40am, Friday, 06'th Feb 2026
Here is how Bayer Aktiengesellschaft (BAYRY) and Align Technology (ALGN) have performed compared to their sector so far this year.
Bayer says its experimental blood thinner cuts risk of stroke recurrence by 26%
12:21pm, Thursday, 05'th Feb 2026
Bayer said on Thursday its experimental blood thinner cut the risk of stroke recurrence by 26% in a late-stage trial, in a fresh boost for CEO Bill Anderson's turnaround efforts.
NEW ORLEANS--(BUSINESS WIRE)--Bayer today presented the results from the global, pivotal Phase III OCEANIC-STROKE study evaluating the use of its investigational, once-daily, oral, Factor XIa inhibito
Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Sees Significant Decline in Short Interest
01:08am, Sunday, 01'st Feb 2026
Bayer Aktiengesellschaft (OTCMKTS:BAYRY - Get Free Report) was the recipient of a large decline in short interest in the month of January. As of January 15th, there was short interest totaling 55,812
Bayer Teams Up with Former Professional Quarterback Tony Romo on ‘Highlights REAL' Campaign
08:30am, Thursday, 29'th Jan 2026
WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer Teams Up with Former Professional Quarterback Tony Romo on ‘Highlights REAL' Campaign.
Bayer Investing More Than $45M CAD to Build World-Class Canola Research and Development Facility in Canada
11:00am, Tuesday, 27'th Jan 2026
CALGARY, Alberta--(BUSINESS WIRE)--Bayer Crop Science today announced an unprecedented $45+ million CAD investment to strengthen Canada's leadership in canola innovation by establishing a cutting-edge
Bayer to Present Results From Phase III OCEANIC-STROKE Study of Asundexian in Secondary Stroke Prevention
07:30am, Tuesday, 27'th Jan 2026
BERLIN--(BUSINESS WIRE)--Bayer today announced that the main results from its global, landmark Phase III study OCEANIC-STROKE of asundexian in secondary stroke prevention, will be presented during two
Bayer Aktiengesellschaft (BAYRY) is a Top-Ranked Value Stock: Should You Buy?
10:41am, Monday, 26'th Jan 2026
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
